Skip to main content

Principal Technologies Inc(PTEC-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.570
Day High0.570
Open:0.570
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Top Stories: Principal Technologies Inc

Select a category then submit the form to load news
Newswire.ca
PRINCIPAL TECHNOLOGIES ENTERS R&D AGREEMENT WITH OXFORD AND DIVESTS OF MAJORITY OWNERSHIP OF E&E CRO CONSULTING
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF PRIVATE PLACEMENT FINANCING
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES PRIVATE PLACEMENT FINANCING
PR Newswire
PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF PRIVATE PLACEMENT FINANCING
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES PRIVATE PLACEMENT FINANCING AND GRANT OF STOCK OPTIONS
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES FINANCING OF OXFORD LICENCE AGREEMENT
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES DEBT SETTLEMENT TRANSACTIONS
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES OXFORD LICENCE AGREEMENT
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES ACQUISTION OF SYNDERMIX
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF PRIVATE PLACEMENT AND SHARES FOR DEBT
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES SHARES FOR DEBT
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES AMENDED STOCK OPTION PLAN AND GRANT OF STOCK OPTIONS
Newswire.ca
PRINCIPAL TECHNOLOGIES PROVIDES UPDATE VIVOSTAT A/S ACQUISITION
Newswire.ca
PRINCIPAL TECHNOLOGIES ANNOUNCES UPSIZING OF PRIVATE PLACEMENT
AI-generated - The Globe and Mail
Principal Technologies: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (PTEC)

Profile

Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.